Production|HQD Launches APEX With 1.47" HD Screen and 5-45W Output

Apr.28.2025
Production|HQD Launches APEX With 1.47" HD Screen and 5-45W Output
HQD recently launched the open e-cigarette APEX, equipped with a 1.47-inch HD touchscreen with 5-45W wide-range power output, supporting three kinds of interchangeable cartridges of 0.4Ω, 0.8Ω and 1.2Ω, and adapted to MTL to DTL modes. The product has been launched on the brand's official website and social media, but has not yet landed on overseas distributor platforms.

Special Statement:

1.This article is intended for internal industry communication only and does not make any recommendations for specific brands or products.

2.This article is prohibited for minors to access.

3.The images presented in this article are used solely to depict facts and are not intended as advertisements for any products.


Product highlights:

 

·The 1.47 inch HD touchscreen interaction: HQD APEX can display real-time battery power, wattage, and work status. 

·Wide range power output of 5-45W: HQD APEX is compatible with 0.4Ω, 0.8Ω, 1.2Ω three-level replaceable pods, supporting MTL (mouth to lung) to DTL (direct to lung) mode switching. 

·Wide range power output: Compared to similar products (such as VOZOL ACE PRO, Geekvape Soul 2 Pod Kit), HQD APEX has the widest power range (5W-45W). 

 

It is worth noting that e-cigarette brand HQD has launched a new open system - APEX on its official website, featuring a 1.47 inch HD touchscreen and supporting 5-45W wide range power output. At present, it has not yet been listed on e-cigarette distributor websites.

 

Equipped with a 1,000mAh battery for wide-range power output of 5-45W

 

2Firsts collected the parameter information of HQD APEX, as shown in the table below:

 

Production|HQD Launches APEX With 1.47
HQD APEX Parameter Information | Mapping: 2Firsts

 

Prior to this, the e-cigarette brand VAPORESSO had also released an open system named "APEX" - the Vaporesso Apex Pod Kit. It is reported that a tactical competitive game called "Apex Legends" launched in 2019 also uses this name.

 

Production|HQD Launches APEX With 1.47
Vaporesso Apex | Image source: Vaporesso

 

From a product specification point of view, the HQD APEX is equipped with a 1,000mAh battery, which is lower compared to similar products such as the VOZOL ACE PRO (1400mAh) and Vaporesso Apex Pod Kit (2000mAh).

 

In addition, the HQD APEX is equipped with three different resistance replaceable pods of 0.4Ω, 0.8Ω, and 1.2Ω, corresponding to an output power range of 5W to 45W. Compared to several other brands such as VOZOL, Geekvape, FRESOR, the HQD APEX has a wider power output range, supporting the switch from MTL (mouth-to-lung) to DTL (direct-to-lung) modes.

 

Production|HQD Launches APEX With 1.47
HQD APEX product information | Image source: HQD

 

It is worth noting that, while the HQD APEX product page displays three different resistance values of replaceable pods (0.4Ω, 0.8Ω, 1.2Ω), the official website states that the product is currently available in 0.8Ω and 1.2Ω variants. However, HQD APEX plans to release a version compatible with 0.4Ω pods in the future.

 

Production|HQD Launches APEX With 1.47
HQD APEX Product Information | Image Source: HQD

 

Equipped with a 1.47-inch HD touchscreen

 

Like many other multi-brand cartridge-style, open-system products that have been introduced before, the HQD APEX is equipped with a 1.47-inch HD touchscreen that can display real-time information such as battery life, power output, and operational status, and supports animated feedback. The product also features airflow adjustment on the side, and includes a side button that provides access to all functions.

 

Production|HQD Launches APEX With 1.47
HQD APEX Product Information | Image Source: HQD

 

Previously, the VOZOL brand launched a pod system e-cigarette product called the VOZOL Ace Max, which also features a 1.47-inch touchscreen display showing data such as power, puff count, and battery level.

 

 

Production|HQD Launches APEX With 1.47
VOZOL Ace Max | Image source: VOZOL

 

Online sales have not been conducted yet

 

Currently, HQD APEX has been launched on the HQD brand official website and is being promoted simultaneously on the brand's Facebook and Instagram official accounts. The HQD brand has now released a variety of open-system products including HQD ZEST, HQD CIRAK, and HQD EOS 2.0.

 

Production|HQD Launches APEX With 1.47
HQD APEX promotional information | Image source: Instagram

 

HQD APEX is currently not available for sale on overseas e-cigarette distributor websites; a search on the UK Medicines and Healthcare products Regulatory Agency (MHRA) e-cigarette product announcement database did not yield any information on HQD APEX, suggesting the product may not be targeted towards the UK market.

 


 

2FIRSTS focuses on providing readers with the latest information on new products in the tobacco industry. We welcome contributions from readers to help us gather and share firsthand information in the e-cigarette field.

 

If you have any unique insights or information, please feel free to contact us anytime via email at info@2firsts.com, or connect with 2Firsts CEO Alan Zhao on LinkedIn.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Latest UK ONS Data: 54% of Vapers Are Former Cigarette Smokers, 26% Also Smoke and 20% Never Smoked Regularly
Latest UK ONS Data: 54% of Vapers Are Former Cigarette Smokers, 26% Also Smoke and 20% Never Smoked Regularly
Former cigarette smokers accounted for an estimated 54% of current e-cigarette users in Great Britain in 2025, while 26% also smoked cigarettes and 20% had never regularly smoked, according to a 2Firsts analysis of Office for National Statistics (ONS) data. Among former cigarette smokers who currently vape, approximately 81% used e-cigarettes daily, compared with about 50% of dual users. The ONS found that 33.8% of current cigarette smokers also vaped in 2025, up from 10.6% in 2014. Approximately 1.1 million adults who had never regularly smoked cigarettes used e-cigarettes, representing 2.9% of that population, compared with 0.2% in 2014. The figures highlight differences in the composition, frequency of use and long-term trends across Britain's vaping population.
DATA
Oct.14
Smoore Seeks to Toss CCELL Price-Fixing Claim as Court Weighs Vertical Distribution Versus Horizontal Conspiracy
Smoore Seeks to Toss CCELL Price-Fixing Claim as Court Weighs Vertical Distribution Versus Horizontal Conspiracy
Smoore and four authorized U.S. CCELL distributors are asking a California federal court to permanently dismiss a core antitrust claim brought by direct purchasers. Plaintiffs allege that Smoore coordinated minimum wholesale prices, customer allocation and limits on price competition among distributors, amounting to a per se unlawful horizontal conspiracy. The defendants say the alleged conduct reflects ordinary vertical relationships between a manufacturer and its distributors. The court previously dismissed a similar claim, and the latest dispute centers on whether the second amended complaint adds sufficient facts to establish a horizontal agreement.
Sep.14
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Philip Morris Japan (PMJ) launched Bold Ruby as a new regular color for the IQOS ILUMA i and IQOS ILUMA i ONE in Japan on September 16, 2026, priced at JPY 6,980 and JPY 3,980, respectively. Initial sales began through IQOS online and physical channels, with convenience stores and selected tobacco retailers set to follow from September 29. Bold Ruby is a regular rather than limited-edition colorway and is available for the ILUMA i and ILUMA i ONE, but not the ILUMA i PRIME. The release does not involve changes to the devices' core hardware or functions.
Sep.22
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14